{
  "timestamp": "2026-03-02T07:47:19.542736+00:00",
  "feed_lines": 1326,
  "recent_feed": [
    "{\"timestamp\":\"2026-03-02T08:30:00Z\",\"topic\":\"compound-synthesis\",\"finding\":\"Stable treasury yields and ai agent coding accuracy suggest to monitor bond benchmarks and codebench scores for duration and tech equity strategy decisions\",\"source\":\"synthesis\"}",
    "{\"timestamp\":\"2026-03-02T07:35:00Z\",\"topic\":\"treasury-bonds\",\"finding\":\"The US 10-year Treasury yield trades near 4.5 percent in early 2026 as the Fed holds rates steady\",\"source\":\"fallback\"}",
    "{\"timestamp\":\"2026-03-02T07:35:00Z\",\"topic\":\"self-improvement\",\"finding\":\"Spaced repetition leverages how your brain naturally forms memories to maximize retention with minimum effort\",\"source\":\"https://www.reviewjane.com/blog/active-recall-spaced-repetition\"}",
    "{\"timestamp\":\"2026-03-02T08:35:00Z\",\"topic\":\"self-improvement\",\"finding\":\"Spaced repetition leverages natural memory formation to maximize retention with minimum effort replacing passive study methods\",\"source\":\"https://www.reviewjane.com/blog/active-recall-spaced-repetition\"}",
    "{\"timestamp\":\"2026-03-02T07:37:33Z\",\"topic\":\"longevity\",\"finding\":\"Rapamycin at 10mg weekly dose prevented muscle loss in women and bone loss in men in phase 4 PEARL trial, showing potential to slow aging-related tissue degeneration\",\"source\":\"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\": \"2026-03-02T07:37:33Z\", \"topic\": \"longevity\", \"finding\": \"Rapamycin 10mg weekly slowed muscle and bone aging in PEARL trial phase I with 50-85yo adults by improving lean mass in women +15% and bone mineral content in men with no serious side effects, suggesting low-dose intermittent use could delay aging markers\", \"source\": \"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\": \"2026-03-02T02:37:00Z\", \"topic\": \"longevity\", \"finding\": \"Rapamycin at 10 mg dose prevented muscle loss in women and bone loss in men in the PEARL clinical trial with no severe side effects reported. Monitor biomarker levels for efficacy and safety in larger trials to confirm results.\", \"source\": \"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\": \"2026-03-02T07:37:33Z\", \"topic\": \"longevity\", \"finding\": \"Rapamycin 10mg weekly in the PEARL trial prevented muscle loss in women and bone loss in men with no serious side effects\", \"source\": \"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\":\"2026-03-02T07:37:00Z\",\"topic\":\"longevity\",\"finding\":\"Rapamycin 10 mg weekly dose showed 0.5 pounds per month lean mass increase in women and significant bone mineral content improvement in men during the 48 week PEARL trial compared to placebo. Monitor immune response markers and consider dosage adjustments with long term use\",\"source\":\"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\":\"2026-03-02T07:37:33Z\",\"topic\":\"longevity\",\"finding\":\"10 mg weekly of rapamycin slowed bone loss in men and muscle loss in women with no serious adverse effects in a 48-week phase 1 trial monitoring as a safer option to resistance exercise for age-related degeneration\",\"source\":\"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\":\"2026-03-02T07:37:33Z\",\"topic\":\"longevity\",\"finding\":\"Rapamycin 10 mg weekly reduced muscle loss in women and bone loss in men during a 48-week trial in the PEARL study with no serious side effects. This suggests rapamycin may mitigate aging at low dosage with safety\",\"source\":\"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\": \"2026-03-02T07:39:33Z\", \"topic\": \"longevity\", \"finding\": \"Rapamycin 10mg/week in PEARL trial prevented muscle loss in women and bone loss in men over 48 weeks with no severe side effects\", \"source\": \"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\":\"2026-03-02T07:37:33Z\",\"topic\":\"longevity\",\"finding\":\"Rapamycin 10 mg weekly slowed bone loss in men (DEXA measurements) and increased lean mass in women by ~0.5 lbs/month in PEARL trial (2026)\",\"source\":\"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\": \"2026-03-02T07:37:33Z\", \"topic\": \"longevity\", \"finding\": \"Rapamycin 10mg improved bone mineral content in men and lean mass in women in the PEARL trial suggesting potential sex-specific anti-aging effects with high dose treatment\", \"source\": \"https://www.nmn.com/news/anti-aging-supplement-rapamycin-slows-muscle-and-bone-aging-in-first-long-term-clinical-trial\"}",
    "{\"timestamp\":\"2026-03-02T08:45:00Z\",\"topic\":\"compound-synthesis\",\"finding\":\"Rapamycin low-dose weekly maintenance aligns with spaced repetition intervals for maximum bone and knowledge retention. Monitor DEXA and codebench scores to optimize both strategies\",\"source\":\"synthesis\"}"
  ],
  "kg_stats": "Entities: 363\nRelationships: 368\nAssociations: 136\nInsights: 0\nDomains: {\n  \"ai-agents\": 81,\n  \"longevity\": 79,\n  \"treasury-bonds\": 53,\n  \"tool-calling\": 47,\n  \"self-improvement\": 39,\n  \"cross-domain\": 17,\n  \"compound-synthesis\": 6,\n  \"local model inference\": 6,\n  \"self_improvement\": 6,\n  \"senolytics\": 4,\n  \"circadian biology\": 3,\n  \"10-year_Treasury_yield\": 2,\n  \"10-year_Treasury_yield_adjustment_intervals\": 2,\n  \"AI development\": 2,\n  \"Longevity\": 2,\n  \"ai-agents,longevity\": 2,\n  \"cross-domain-associations\": 2,\n  \"finance-cycles\": 2,\n  \"spaced_repetition_intervals\": 2,\n  \"tool-calling-improvements\": 2,\n  \"treasury\": 2,\n  \"treasury-bounds\": 2\n}",
  "last_synthesis": "daily-synthesis-2026-02-21.md",
  "synthesis_content": "# Daily Synthesis - 2026-02-21 (Cycle 2 - Evening Update)\n\nGenerated by: zeke-reason.sh (Claude Code autonomous reasoning layer)\nFeed entries analyzed: 193 total, 30 scored across 2 evaluation cycles\nKG state: 75 entities, 59 relationships, 9 associations, 8 domains\n\n---\n\n## System Status: DEGRADED\nALL 8 overnight queue jobs failed with gateway timeouts this morning (12:56-14:17 UTC).\nGateway PID 95262 is running, Spark reachable at 10.0.0.143:11434. All quality entries\ntoday came from the afternoon Reason cycle (Claude Opus), not the overnight Spark queue.\n\n---\n\n## 3 Key Strategic Insights\n\n### 1. TLT PRIORITY: Position Breakeven Analysis at 4.85% 20-Year Yield\n\nThe 20-year yield at 4.85% (DGS20, 2/19/2026) puts TLT approximately at $87-89.\nUsing TLT effective duration of ~17 years:\n\n| Position | Strike | Qty  | Approx Breakeven TLT | Required Yield Drop | Probability |\n|----------|--------|------|----------------------|---------------------|-------------|\n| $90C     | $90    | 650  | ~$93-95 at expiry    | ~55-85bps to 4.0%   | Moderate    |\n| $95C     | $95    | 300  | ~$98-100 at expiry   | ~85-105bps to 3.8%  | Low-Mod     |\n| $101C    | $101   | 3150 | ~$104-107 at expiry  | ~115bps to 3.7%     | Low         |\n| Shares   | -      | 1868 | At cost basis        | Any decline          | Moderate    |\n\nDuration math: 17yr \u00d7 0.85% yield drop = ~14.5% price increase \u2192 TLT $87 \u00d7 1.145 = ~$100.\nSo a move from 4.85% to 4.0% gets TLT to ~$100 \u2014 making $90C and $95C profitable, but\n$101C marginal. The $101C (3150 contracts) needs a recession-level catalyst.\n\nMacro signals this week:\n- Fed minutes: hawkish pause confirmed (bearish near-term for bonds)\n- Jan jobs: 130k (below 150k trend \u2014 mildly supportive)\n- 10-year: 4.1% (stable, not breaking lower)\n- RIKB auction data captured was ICELANDIC bonds (search error) \u2014 US data still needed\n- MOVE index level: NOT YET CAPTURED \u2014 critical gap\n\nTLT VERDICT: No immediate catalyst for the ~115bps rally $101C needs. The $90C position\nis more realistic. Watch: March FOMC (3/19), Q1 GDP, credit spread widening. Time decay\naccelerating \u2014 11 months to 1/15/27 expiry.\n\n### 2. Longevity Research Hit Peak Productivity \u2014 4 Score-5 Entries\n\nThe afternoon Reason cycle produced the best research day since tracking began:\n\na) p-tau217 commercial availability: 8 labs now offering testing (Labcorp test code\n   484390, Mayo PT217, Lucent, Genova, TrueHealthLabs, ALZpath, C2N, Quest). Cost\n   $195-$400. FDA cleared Lumipulse G pTau217/AB42 ratio May 2025. Insurance coverage\n   expanding. ACTIONABLE: Matt should consider testing given 3-4 year prediction window.\n\nb) AKL003 Phase 1b: Launched 2/19/2026 (2 days ago), actively recruiting ages 25-75.\n   Alpha Klotho mRNA in LNPs, IV administration, 2:1 randomization, single site at GARM\n   Clinic in Prospera, Roatan, Honduras. NOT on ClinicalTrials.gov (NCT07216781 unclear).\n\nc) DMTF1: Science Advances Jan 2026 (DOI: 10.1126/sciadv.ady5905). DMTF1 upregulation\n   rescues aged neural",
  "priorities_updated": "2026-03-01T10:00:52.261529+00:00",
  "priorities_content": "# Research Priorities \u2014 Updated 2026-03-01\n\n## Tier 1 \u2014 Actively Monitor\n1. **Rapamycin clinical trials** \u2014 PEARL trial Phase 2 ongoing; watch for full\n   results. Human safety/efficacy data is the gap to fill. Source: pmc.ncbi.nlm.nih.gov\n2. **AI agent reliability** \u2014 Tool-calling accuracy is the limiting factor for\n   Zeke autonomy. Monitor Berkeley BFCL leaderboard for model improvements.\n   Current ceiling: ~88% multi-step. Gap: real-world reliability below benchmark.\n\n## Tier 2 \u2014 Periodic Check (Weekly)\n3. **Spaced repetition implementation** \u2014 Apply double-spacing intervals to Zeke\n   feed review. Research is settled; priority shifts to implementation.\n4. **Treasury yields** \u2014 10Y at 3.95%, Fed holding. Monitor for rate cut signals\n   that affect TLT position.\n\n## Tier 3 \u2014 Diminishing Returns (Reduce Feed Weight)\n5. **tool-calling general** \u2014 Saturated. Consolidate to monthly summary.\n6. **compound-synthesis** \u2014 Derivable locally; not worth dedicated feed slots.\n7. **AI agent benchmarks (general)** \u2014 High noise/signal ratio; filter to\n   specific named tools only (Claude Code, Lovable, Cursor).\n\n## Feed Health Notes\n- Dedup pass needed: tool-calling topic has 8+ near-identical entries this cycle\n- compound-synthesis entries should be generated locally, not ingested as feed\n- Quality scoring working well; 4-5 scores are surfacing genuinely useful content\n",
  "gpu_stats": {
    "status": "OK",
    "gpu_util_pct": 0.0,
    "temp_c": 52.0,
    "power_w": 12.49,
    "gpu_name": "NVIDIA GB10"
  },
  "gateway_config": {
    "sessionTimeoutMs": "NOT SET",
    "timeoutMs": "NOT SET",
    "elevated": {},
    "byProvider": {
      "spark/qwen3:8b": {
        "allow": [
          "read",
          "memory_search",
          "session_status"
        ],
        "count": 3
      },
      "spark/qwen3-32b-32k": {
        "allow": [
          "exec",
          "read",
          "web_search",
          "memory_search",
          "web_fetch"
        ],
        "count": 5
      },
      "spark/deepseek-r1:32b": {
        "allow": [
          "exec",
          "read",
          "web_search",
          "memory_search",
          "web_fetch"
        ],
        "count": 5
      },
      "spark/deepseek-r1-32b-32k": {
        "allow": [
          "exec",
          "read"
        ],
        "count": 2
      }
    }
  },
  "gateway_process": {
    "pid": "95513",
    "memory_pct": "2.9",
    "uptime": "05:47:09",
    "status": "RUNNING"
  },
  "spark_status": {
    "status": "ONLINE",
    "loaded_models": [
      {
        "name": "qwen3:8b",
        "size_gb": 6.0
      },
      {
        "name": "nomic-embed-text:latest",
        "size_gb": 0.6
      },
      {
        "name": "qwen3-32b-32k:latest",
        "size_gb": 29.1
      }
    ]
  },
  "feed_quality": {
    "malformed_json": 2,
    "literal_timestamps": 0,
    "duplicates": 59,
    "no_new_dev": 0,
    "total": 639,
    "error_rate": 9.5
  },
  "crontab_status": {
    "total_entries": 7,
    "active": 7,
    "disabled_for_maint": 0,
    "has_queue": false,
    "has_overnight": false,
    "has_reason": false,
    "has_status_push": false
  },
  "last_jobs": [
    {
      "name": "tool-calling",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:31 AM",
      "cycle_num": 24
    },
    {
      "name": "compound-synthesis",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:31 AM",
      "cycle_num": 24
    },
    {
      "name": "treasury-bonds",
      "status": "fail",
      "duration": 29,
      "grew": 0,
      "issues": [],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "self-improvement",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "longevity",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "ai-agents",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "tool-calling",
      "status": "success",
      "duration": 96,
      "grew": 1,
      "issues": [],
      "valid_entries": 1,
      "broken_entries": 0,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "compound-synthesis",
      "status": "success",
      "duration": 280,
      "grew": 6,
      "issues": [],
      "valid_entries": 6,
      "broken_entries": 0,
      "cycle_time": "2:34 AM",
      "cycle_num": 26
    },
    {
      "name": "treasury-bonds",
      "status": "fail",
      "duration": 4,
      "grew": 0,
      "issues": [],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "self-improvement",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "longevity",
      "status": "success",
      "duration": 151,
      "grew": 7,
      "issues": [],
      "valid_entries": 7,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "ai-agents",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "tool-calling",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "compound-synthesis",
      "status": "success",
      "duration": 92,
      "grew": 1,
      "issues": [],
      "valid_entries": 1,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 27
    },
    {
      "name": "treasury-bonds",
      "status": "success",
      "duration": 27,
      "grew": 2,
      "issues": [],
      "valid_entries": 2,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    },
    {
      "name": "self-improvement",
      "status": "success",
      "duration": 98,
      "grew": 2,
      "issues": [],
      "valid_entries": 2,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    },
    {
      "name": "longevity",
      "status": "success",
      "duration": 105,
      "grew": 3,
      "issues": [],
      "valid_entries": 3,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    },
    {
      "name": "ai-agents",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    },
    {
      "name": "tool-calling",
      "status": "success",
      "duration": 226,
      "grew": 3,
      "issues": [],
      "valid_entries": 3,
      "broken_entries": 0,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    },
    {
      "name": "compound-synthesis",
      "status": "unknown",
      "duration": 0,
      "grew": 0,
      "issues": [
        "spark_locked"
      ],
      "valid_entries": null,
      "broken_entries": null,
      "cycle_time": "2:47 AM",
      "cycle_num": 25
    }
  ],
  "recent_cycles": [
    {
      "cycle": 24,
      "window": "overnight",
      "timestamp": "2026-03-02T02:31:54.810519",
      "time_display": "2:31 AM",
      "feed_growth": 27,
      "jobs": [
        {
          "name": "treasury-bonds",
          "status": "success",
          "duration": 208,
          "grew": 6,
          "issues": [],
          "valid_entries": 6,
          "broken_entries": 0,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        },
        {
          "name": "self-improvement",
          "status": "success",
          "duration": 126,
          "grew": 7,
          "issues": [],
          "valid_entries": 7,
          "broken_entries": 0,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        },
        {
          "name": "longevity",
          "status": "success",
          "duration": 99,
          "grew": 2,
          "issues": [],
          "valid_entries": 2,
          "broken_entries": 0,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        },
        {
          "name": "ai-agents",
          "status": "success",
          "duration": 332,
          "grew": 8,
          "issues": [],
          "valid_entries": 6,
          "broken_entries": 2,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        },
        {
          "name": "tool-calling",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        },
        {
          "name": "compound-synthesis",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:31 AM",
          "cycle_num": 24
        }
      ]
    },
    {
      "cycle": 26,
      "window": "overnight",
      "timestamp": "2026-03-02T02:34:58.107935",
      "time_display": "2:34 AM",
      "feed_growth": 15,
      "jobs": [
        {
          "name": "treasury-bonds",
          "status": "fail",
          "duration": 29,
          "grew": 0,
          "issues": [],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        },
        {
          "name": "self-improvement",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        },
        {
          "name": "longevity",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        },
        {
          "name": "ai-agents",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        },
        {
          "name": "tool-calling",
          "status": "success",
          "duration": 96,
          "grew": 1,
          "issues": [],
          "valid_entries": 1,
          "broken_entries": 0,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        },
        {
          "name": "compound-synthesis",
          "status": "success",
          "duration": 280,
          "grew": 6,
          "issues": [],
          "valid_entries": 6,
          "broken_entries": 0,
          "cycle_time": "2:34 AM",
          "cycle_num": 26
        }
      ]
    },
    {
      "cycle": 27,
      "window": "overnight",
      "timestamp": "2026-03-02T02:47:13.449401",
      "time_display": "2:47 AM",
      "feed_growth": 11,
      "jobs": [
        {
          "name": "treasury-bonds",
          "status": "fail",
          "duration": 4,
          "grew": 0,
          "issues": [],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        },
        {
          "name": "self-improvement",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        },
        {
          "name": "longevity",
          "status": "success",
          "duration": 151,
          "grew": 7,
          "issues": [],
          "valid_entries": 7,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        },
        {
          "name": "ai-agents",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        },
        {
          "name": "tool-calling",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        },
        {
          "name": "compound-synthesis",
          "status": "success",
          "duration": 92,
          "grew": 1,
          "issues": [],
          "valid_entries": 1,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 27
        }
      ]
    },
    {
      "cycle": 25,
      "window": "overnight",
      "timestamp": "2026-03-02T02:47:18.186547",
      "time_display": "2:47 AM",
      "feed_growth": 15,
      "jobs": [
        {
          "name": "treasury-bonds",
          "status": "success",
          "duration": 27,
          "grew": 2,
          "issues": [],
          "valid_entries": 2,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        },
        {
          "name": "self-improvement",
          "status": "success",
          "duration": 98,
          "grew": 2,
          "issues": [],
          "valid_entries": 2,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        },
        {
          "name": "longevity",
          "status": "success",
          "duration": 105,
          "grew": 3,
          "issues": [],
          "valid_entries": 3,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        },
        {
          "name": "ai-agents",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        },
        {
          "name": "tool-calling",
          "status": "success",
          "duration": 226,
          "grew": 3,
          "issues": [],
          "valid_entries": 3,
          "broken_entries": 0,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        },
        {
          "name": "compound-synthesis",
          "status": "unknown",
          "duration": 0,
          "grew": 0,
          "issues": [
            "spark_locked"
          ],
          "valid_entries": null,
          "broken_entries": null,
          "cycle_time": "2:47 AM",
          "cycle_num": 25
        }
      ]
    }
  ],
  "evaluation_count": 30,
  "recent_evaluations": [
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 184, \"feed_ts\": \"2026-02-21T15:30:00Z\", \"topic\": \"longevity research\", \"subtopic\": \"p-tau217 commercial availability\", \"novelty_score\": 5, \"reasoning\": \"Extremely detailed: 8 named labs (Labcorp test code 484390, Mayo PT217, Lucent, Genova, TrueHealthLabs, ALZpath, C2N, Quest), exact pricing ($195-$400), FDA clearance status, insurance implications. Directly actionable for Matt.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 185, \"feed_ts\": \"2026-02-21T15:31:00Z\", \"topic\": \"longevity research\", \"subtopic\": \"AKL003 Phase 1b trial\", \"novelty_score\": 5, \"reasoning\": \"Named trial launched 2 days ago, specific design (randomized double-blind 2:1), population (25-75), dosing schedule (IV q4wks x2), single site Honduras. Answered our P1 question on enrollment status.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 186, \"feed_ts\": \"2026-02-21T15:32:00Z\", \"topic\": \"longevity research\", \"subtopic\": \"DMTF1 neural stem cell\", \"novelty_score\": 5, \"reasoning\": \"DOI 10.1126/sciadv.ady5905, PubMed 41481722, specific mechanism (DMTF1 > Arid2/Ss18 > SWI/SNF > H3K27ac > E2F), named institution NUS. Excellent primary source depth.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 187, \"feed_ts\": \"2026-02-21T15:33:00Z\", \"topic\": \"longevity research\", \"subtopic\": \"metformin exercise blunting\", \"novelty_score\": 5, \"reasoning\": \"3 named RCTs (MASTERS 2019, Rutgers 2025, MET-PREVENT 2025 Lancet), specific figures (p=.003, 50% fitness blunting, 1700mg/d dose), mechanistic detail (mitochondrial complex I). Critical protocol guidance.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 188, \"feed_ts\": \"2026-02-21T15:34:00Z\", \"topic\": \"AI agent architectures\", \"subtopic\": \"ring attention million-token\", \"novelty_score\": 3, \"reasoning\": \"Good technical detail (Meta 77s prefill, O(n) complexity, Pass-KV) but context window sizes well-known. Production timeline speculative. Moderate relevance to Zeke architecture.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 189, \"feed_ts\": \"2026-02-21T12:56:06Z\", \"topic\": \"longevity\", \"subtopic\": \"PEARL follow-up\", \"novelty_score\": 1, \"reasoning\": \"Malformed JSON (unquoted timestamp, stringified arrays). Content is null: explicitly states no new data. Confirms known gap.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 190, \"feed_ts\": \"2026-02-21T12:57:00Z\", \"topic\": \"treasury-bonds\", \"subtopic\": \"RIKB auction data\", \"novelty_score\": 2, \"reasoning\": \"RIKB = Icelandic government bonds, NOT US Treasury 20-year. Wrong search result for our TLT focus. Bid-to-cover data is specific but irrelevant to portfolio.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 191, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"ai-agents\", \"subtopic\": \"Microsoft Agent Framework duplicate\", \"novelty_score\": 1, \"reasoning\": \"Duplicate of line 183 with less detail. Literal shell variable as timestamp. No new information.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 192, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"self-improvement\", \"subtopic\": \"novelty-seeking habits\", \"novelty_score\": 2, \"reasoning\": \"Vague insights with fabricated confidence scores (0.85, 0.78) but no source citations. Literal shell variable timestamp. Likely model confabulation.\"}",
    "{\"timestamp\": \"2026-02-21T14:30:00Z\", \"eval_date\": \"2026-02-21\", \"eval_cycle\": 2, \"feed_line\": 193, \"feed_ts\": \"LITERAL_VAR\", \"topic\": \"tool-calling\", \"subtopic\": \"no developments\", \"novelty_score\": 1, \"reasoning\": \"Explicitly no new developments. Correct to skip per priorities (DEPRIORITIZED). Literal shell variable timestamp.\"}"
  ],
  "self_heal_log": "# Self-Heal Log\n\n## 2026-02-26 \u2014 Dashboard Fix (Manual)\n- Cleaned stale byProvider entries (removed unused models)\n- Updated ops-status.md (was showing DEGRADED from Feb 21)\n- Deployed MCP watchdog (5-min cron, auto-restart + Telegram)\n- quality-eval job: diagnosed as failing, needs scheduler prompt fix\n\n## 2026-02-26 \u2014 MCP Watchdog Deployed\n- ~/zeke-mcp-watchdog.py checks process, port, SSE every 5 min\n- Auto-restarts via launchctl, Telegram alerts on failure\n- Added to crontab alongside existing system watchdog\n\n## 2026-02-22 \u2014 L2 Autonomy Deployed  \n- Watchdog every 10min auto-repairs scheduler via launchctl\n- Telegram alerts on failures\n- Verified: scheduler kill \u2192 repaired in 35s\n",
  "ops_status": "# Operational Status \u2014 2026-02-26\n\n## System Health: HEALTHY\n\n### Pipeline Summary (automated via Python scheduler)\n- Scheduler: Running, daytime+overnight windows\n- Feed: 1,029 entries, growing ~30-40/overnight cycle\n- Success rate: 89% (89/100 jobs today)\n- Cost: $0/day (all local Spark models)\n- Timeouts: 0 today\n\n### Active Research Jobs (Python scheduler)\n- treasury-bonds: \u2705 running\n- longevity: \u2705 running  \n- ai-agents: \u2705 running\n- self-improvement: \u2705 running\n- tool-calling: \u26a0\ufe0f intermittent failures\n- compound-synthesis: \u2705 running\n- quality-eval: \u274c failing (needs investigation)\n\n### Active OpenClaw Cron Jobs\n- tlt-alert-scanner: \u2705 enabled (market hours)\n- association-engine: \u2705 enabled (every 4h)\n- system-health-alert: \u2705 enabled (every 2h)\n- kg-extractor: \u2705 enabled (every 2h)\n- system-doctor: \u2705 enabled (every 2h)\n\n### Infrastructure\n| Component       | Status  | Notes                              |\n|-----------------|---------|-------------------------------------|\n| Gateway         | RUNNING | 23+ hours uptime                    |\n| Spark server    | ONLINE  | qwen3-32b-32k, nomic-embed, qwen3:8b |\n| MCP Server      | RUNNING | Port 8100, Tailscale funnel active  |\n| Dashboard       | LIVE    | GitHub Pages + local:3333           |\n| Watchdogs       | ACTIVE  | System (10min) + MCP (5min)         |\n\n### Automation Layers\n- L1 (Execution): \u2705 DEPLOYED \u2014 scheduler, guardian, quality gate\n- L2 (Oversight): \ud83d\udd28 IN PROGRESS (~60%) \u2014 dashboard live, watchdogs active, quality-eval broken\n- L3 (Intelligence): \ud83d\udccb PLANNED \u2014 cross-domain synthesis, prompt evolution\n",
  "zeke-queue_tail": [],
  "zeke-reason-error_tail": [],
  "cron_job_count": 7,
  "strategic_context": "# Zeke Strategic Context\nLast distilled: 2026-03-01\n\n## System Architecture\n\n**Core Inference Stack**\n- Primary: Claude Sonnet (main chat, quality priority, fallback safety)\n- Local: Spark DGX @ 10.0.0.143:11434 (qwen3-32b, glm-4.7-flash, qwen2.5-coder:32b)\n- Routing rule: OpenClaw agent sessions \u2192 Claude only (tools unreliable on local); cron + learning \u2192 local models ($0 variable cost)\n- Fallback chain: spark/qwen3-32b \u2192 spark/glm-4.7-flash \u2192 anthropic/claude-sonnet\n\n**Memory & Knowledge**\n- Embedding model: nomic-embed-text (local, 7B, lossless)\n- Vector DB: ChromaDB (34/38 files indexed, 113 chunks, fresh)\n- Canonical domains: 5 \u2014 treasury-bonds, camel-finance, compound-synthesis, longevity-research, ai-agents\n- Learning feed: 527 entries, 12 pending queue tasks, 2 pending approvals\n\n**Task Execution**\n- Queue daemon: spark-work-queue.py (monitors improvement-queue.md, auto-schedules high-priority synthesis)\n- Approval system: zeke-approval.py (8 decision types, priority+expiry flow, human-in-the-loop wiring live)\n- Cost tracking: cost-log.md (baseline established Feb 16, daily spend hardcap rules in place)\n- Health monitor: 30m heartbeat on spark/qwen3-32b, tunnel recovery auto-enabled\n\n**Operational State** (as of 2026-03-01T17:34 UTC)\n- Blocks deployed: 1 (queue daemon) + 2 (domain scrub) + 3 (RAG feedback) + 4 (learning synthesis) + 5 (financial ingestion) + 6 (quality-weights optimization) + 7 (approval system)\n- Block 8 (nightly memory distillation) queued for next cycle\n- LaunchAgents active: 6/7 (daily financial fetch 6:15am, quality eval 7am, learning jobs 9pm-3am, maintenance window 2am-5am)\n\n## Active Positions\n\n**Treasury Bonds (TLT)** \u2014 STRONG domain (4.0/4.0 quality tier)\n- MacroAlf RSS ingestion: 4 articles/run, working\n- TreasuryDirect auction calendar: working\n- FedWatch + Yahoo Finance: blocked by auth, auto-queued as Spark research tasks\n- Last synthesis: TLT performance tracking vs inflation, Fed policy impact on rates\n- Next: integrate with camel-finance position tracking\n\n**Camel Finance** \u2014 OK domain, declining (3.24/4.0, threshold 3.0)\n- Extraction quality lagging; remediation task queued by quality-weights.py (2026-03-01)\n- Financial metrics: personal asset tracking, allocation rebalancing\n- Learning synthesis: 5+ sessions on personal finance tax-efficient strategies\n- Next: improve scraper accuracy or source diversification\n\n**Compound Synthesis** \u2014 OK domain, declining trend\n- Identified as operation (not core domain) after Feb 28 audit\n- Topics: cross-domain connection-finding (TLT+macro \u2192 crypto volatility, AI agents \u2192 system design patterns)\n- Audit task queued by quality-weights.py on Feb 28\n- Next: evaluate if should remain active or deprecate to preserve learning velocity\n\n**Longevity Research** \u2014 Sustained interest, secondary priority\n- Huberman Lab tracking: neuroscience, learning, recovery protocols\n- Peter Attia: Alzheimer's prevention, midlife interventions\n- Bryan Johnson: Blueprint health monitoring\n- 5"
}